Inactive Instrument

Spark Therapeutics, Inc.

US84652J1034

Biotechnology & Medical Research

Spark Therapeutics, Inc. Names Lota Zoth to the Board of Directors

January 06, 2016 at 04:01 pm EST

Spark Therapeutics, Inc. announced that Lota Zoth, CPA, a long-time financial executive at multiple publicly listed companies, has been named to the company's Board of Directors.

Latest news about Spark Therapeutics, Inc.

Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	23-10-14	CI
Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	23-01-27	CI
Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	22-12-12	CI
Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022	22-02-23	CI
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	21-12-16	CI
Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII Expression that Significantly Reduced Bleeding in Hemophilia A Patients	21-11-17	CI
CombiGene in Billion-Dollar Deal with Spark Therapeutics	21-10-12	CI
NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease	21-09-07	CI
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date	21-07-21	CI
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform	21-04-13	CI
Spark Therapeutics Appoints Cynthia Pussinen as Chief Technical Officer	21-02-25	CI
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress	21-02-05	CI
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease	21-02-01	CI
Spark Therapeutics Appoints Michael Retterath as Chief Strategy Officer	20-11-16	CI
Spark Therapeutics, Inc. Appoints Gallia Levy as Chief Medical Officer	20-08-10	CI
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress	20-07-12	CI
Spark Therapeutics, Inc. Demonstrates Role of Ides in Enabling of Gene Therapy in the Presence of Neutralizing Anti-Aav Antibodies Published in Nature Medicine	20-06-01	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P TMI Index	19-12-23	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P Global BMI Index	19-12-23	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P Biotechnology Select Industry Index	19-12-23	CI
Trouble for Boeing, Netflix expands, Amazon toughens up against Fedex…	19-12-17
Spark Therapeutics, Inc. Announces Board Changes	19-12-17	CI
Spark Therapeutics : Roche to complete $4.3 billion Spark deal as regulators give all clear	19-12-17	RE
Spark Therapeutics : Roche to complete $4.3 billion Spark deal as regulators give all clear	19-12-17	RE
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from NASDAQ Composite Index	19-12-17	CI

Chart Spark Therapeutics, Inc.

Duration

Period

More charts

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
ARGENX SE	-3.55%	21.6B
BIONTECH SE	-12.38%	22.31B
GENMAB A/S	-6.54%	19.19B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B

Bio Therapeutic Drugs